As an innovative initiative aiming to develop a personalised prediction tool to assist in managing the recurrence of autoimmune diseases in patients, the PARADISE Project (PersonAlisation of RelApse risk in autoimmune DISEases) has officially been launched with a kick-off held on the 3rd and 4th of April 2023, featuring presentations from ADAPT Centre researchers Matthieu Coq, Yagmur Dogay, Angel George and Jamsheela Nazeer. The project is coordinated by ADAPT Principal Investigator at Trinity College Dublin, Prof. Mark Little, with partners across several institutions in Europe, including FIRALIS!
According to the PARADISE consortium, autoimmune diseases affect 10% of all adults and in particular women, who are the most affected class of patients by these diseases. Medications to manage the desease have a significant global healthcare costs while suppressing the immune system, which often leads to patients becoming more susceptible to increased infections and risk of cancer. A key target for research by the PARADISE consortium is the prediction of relapse, or prediction of the cases with relapse being extremely unlikely, for patients with Vasculitis so that medication doses can be personalized, or in some cases, stopped entirely.
As artificial intelligence (AI) applications are coming under intense EU scrutiny, the consortium will also co-develop an “AI transparency notice” to explain the clinical outputs of PARADISE personalized prediction tools.
Project partners include:
- Anto Čartolovni, Catholic University of Croatia, Croatia
- Elisa Pin, KTH Royal Institute of Technology, Sweden
- Harald Binder, University of Freiburg, Germany
- Stéphanie Boutillier, Firalis S.A., France
- Dipak Kalra, The European Institute for Innovation through Health Data AISBL, Belgium
- Julie Power, Vasculitis Ireland Awareness, Ireland
- Juliana Bordignon Draibe, Bellvitge Biomedical Research Institute, Barcelona, Spain
FIRALIS Team joins the PARADISE project as a key participant, contributing with its biomarker experience, on the transcriptomic profiling, as well as canalyzing its S&M workforce and know-how to establish a market positioning for the ultimate tool to be developed.